The global market for Intravenous Immunoglobulin (IVIg) was estimated at US$20.8 Billion in 2024 and is projected to reach US$34.0 Billion by 2030, growing at a CAGR of 8.5% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Intravenous Immunoglobulin (IVIg) market.
The administration of IVIG is generally carried out intravenously in a clinical setting, where the dosage and frequency are meticulously tailored to the patient`s specific medical needs and body weight. This personalized approach ensures that patients receive optimal treatment effectiveness with minimized side effects. However, IVIG therapy can be accompanied by adverse reactions ranging from mild symptoms like headaches and fatigue to more severe conditions such as allergic reactions, necessitating careful monitoring and preemptive measures by healthcare providers to mitigate these effects. Recent advancements have seen the development of subcutaneous alternatives and innovations like M254, a derivative with enhanced anti-inflammatory properties, showing promise in clinical trials for providing a more potent and better-tolerated treatment option than traditional IVIG, particularly for autoimmune conditions.
The demand for IVIG is driven by its diverse medical applications, effectiveness in treating rare diseases, and its increasing use in early intervention and maintenance therapy for chronic conditions. Technological advancements in IVIG production have enhanced its safety and scalability, reducing side effects and improving overall tolerability for patients. Additionally, global health initiatives and specialized immunology centers have integrated IVIG into national treatment guidelines, promoting its use. Patient advocacy and education have further increased demand, as more patients seek access to this essential treatment. Regulatory support, particularly for orphan drugs, has expedited the availability of IVIG, enhancing access to this crucial medication in both established and emerging markets. These factors collectively underscore the growing importance of IVIG in modern healthcare, pointing towards an expanded role and increased adoption in medical settings globally.
Global Intravenous Immunoglobulin (IVIg) Market - Key Trends and Drivers Summarized
Intravenous Immunoglobulin (IVIG) is a critical component in medical treatments, providing necessary antibodies to those with inadequate immune defenses. Derived from the plasma of thousands of donors, IVIG encompasses a wide array of antibodies essential for combating various pathogens, making it indispensable for individuals with immunodeficiency disorders. By supplementing the body`s antibody requirement, IVIG offers robust protection against a multitude of infections, crucial for patients whose bodies cannot produce sufficient antibodies. Additionally, IVIG plays a significant role in treating autoimmune diseases, where the body`s immune system erroneously attacks its own cells. By introducing a high concentration of antibodies, IVIG helps mitigate this misguided immune response, offering relief for conditions such as immune thrombocytopenia and autoimmune hemolytic anemia, among others.The administration of IVIG is generally carried out intravenously in a clinical setting, where the dosage and frequency are meticulously tailored to the patient`s specific medical needs and body weight. This personalized approach ensures that patients receive optimal treatment effectiveness with minimized side effects. However, IVIG therapy can be accompanied by adverse reactions ranging from mild symptoms like headaches and fatigue to more severe conditions such as allergic reactions, necessitating careful monitoring and preemptive measures by healthcare providers to mitigate these effects. Recent advancements have seen the development of subcutaneous alternatives and innovations like M254, a derivative with enhanced anti-inflammatory properties, showing promise in clinical trials for providing a more potent and better-tolerated treatment option than traditional IVIG, particularly for autoimmune conditions.
The demand for IVIG is driven by its diverse medical applications, effectiveness in treating rare diseases, and its increasing use in early intervention and maintenance therapy for chronic conditions. Technological advancements in IVIG production have enhanced its safety and scalability, reducing side effects and improving overall tolerability for patients. Additionally, global health initiatives and specialized immunology centers have integrated IVIG into national treatment guidelines, promoting its use. Patient advocacy and education have further increased demand, as more patients seek access to this essential treatment. Regulatory support, particularly for orphan drugs, has expedited the availability of IVIG, enhancing access to this crucial medication in both established and emerging markets. These factors collectively underscore the growing importance of IVIG in modern healthcare, pointing towards an expanded role and increased adoption in medical settings globally.
Scope of Study:
The report analyzes the Intravenous Immunoglobulin (IVIg) market in terms of units by the following Segments, and Geographic Regions/Countries:- Segments: Type (IgA, IgE, IgG, IgM, IgD); End-Use (Hospitals, Clinics, Homecare Settings)
- Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the IgA segment, which is expected to reach US$13.7 Billion by 2030 with a CAGR of a 10.6%. The IgE segment is also set to grow at 7.6% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, estimated at $5.7 Billion in 2024, and China, forecasted to grow at an impressive 7.9% CAGR to reach $5.2 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Intravenous Immunoglobulin (IVIg) Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Intravenous Immunoglobulin (IVIg) Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Intravenous Immunoglobulin (IVIg) Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of players such as Bharat Serums and Vaccines Limited, Biotest AG, China Biologic Products, Inc., CSL Limited, Grifols, S.A. and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Some of the 24 companies featured in this Intravenous Immunoglobulin (IVIg) market report include:
- Bharat Serums and Vaccines Limited
- Biotest AG
- China Biologic Products, Inc.
- CSL Limited
- Grifols, S.A.
- Hualan Biological Engineering Inc.
- Kedrion S.p.A.
- LFB Group
- Octapharma AG
- Shanghai RAAS Blood Products Co., Ltd.
- Shire plc
- Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include:
- Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs.
- Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes segmentation by product, technology, type, material, distribution channel, application, and end-use, with historical analysis since 2015.
- Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends.
- Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape.
- Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players.
- Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities.
- Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage.
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIV. COMPETITION
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
III. MARKET ANALYSIS
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Bharat Serums and Vaccines Limited
- Biotest AG
- China Biologic Products, Inc.
- CSL Limited
- Grifols, S.A.
- Hualan Biological Engineering Inc.
- Kedrion S.p.A.
- LFB Group
- Octapharma AG
- Shanghai RAAS Blood Products Co., Ltd.
- Shire plc
- Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 184 |
| Published | July 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 20.8 Billion |
| Forecasted Market Value ( USD | $ 34 Billion |
| Compound Annual Growth Rate | 8.5% |
| Regions Covered | Global |
